Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

India's Ranbaxy probes 'possible' glass in drug  Join our daily free Newsletter

MENAFN - AFP - 01/12/2012

No. of Ratings : 0
Add to Mixx!


 


(MENAFN - AFP) Indian drug giant Ranbaxy has ceased production of its generic version of cholesterol-busting drug Lipitor until it probes the issue of "possible" glass particles in some lots, a statement said on Saturday.

The problem is the latest to beset the generics heavyweight, India's largest drug firm by sales, which reached a deal with US regulators earlier this year over a lengthy quality compliance dispute in which it promised tighter checks.

Ranbaxy on November 9 informed its customers of a "voluntary recall" of some lots of its atorvastatin tablets -- the generic version of Lipitor, the US Food and Drug Administration (USFDA) said in statement on its website.

The lots of atorvastatin, packaged in bottles of 90 and 500 tablets, are being recalled "due to possible contamination with very small glass particles similar to the size of a grain of sand", the statement added.

"Ranbaxy decided to stop making atorvastatin until the company has thoroughly investigated the cause of the contamination and remedied the problem," the US agency said.

Demand for the cholesterol lowering drug in the United States has been a big boost to Ranbaxy's sales.

The firm, headquartered in the New Delhi satellite city of Gurgaon, supplies the generic version of Lipitor to the US market from two facilities -- New Jersey-based Ohm Laboratories and its Mohali plant in India.

"At this time, we have not received any reports of patient harm due to glass particulates that may be in the recalled product," USFDA added.

Ranbaxy, bought by Japan's Daiichi Sankyo for 4.6 billion in 2008, launched the drug in the US market a year ago. Ranbaxy's recall involves 41 lots with mid-2014 expiry dates.

Ranbaxy, which has factories in eight countries, has grown by selling cheap copies of branded drugs that have gone off-patent, and through challenges to patents owned by Western companies.

Daiichi Sankyo bought control of the Indian firm to diversify globally and to break into the fast-growing generics market.

But Daiichi Sankyo faced an uphill battle to turn around Ranbaxy after US authorities alleged the company falsified data, failed to prevent contamination of medicines and kept poor records.


 






  MENA News Headlines


 
Click to Apply






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help